Another meta-analysis of nine selected studies (196 patients with HCC and 491 HCC lesions) demonstrated that [68Ga]Ga-PSMA-11 PET showed a high sensitivity of 89.9% (95% CI 78.5-95.5) on a per-patient analysis for HCC and that this rate increased to 94.5% (95% CI 82.9-98.4) on a per-lesion analysis (52). This evidence concerns the gene FOLH1 and hepatocellular carcinoma.